These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Singerman LJ; Masonson H; Patel M; Adamis AP; Buggage R; Cunningham E; Goldbaum M; Katz B; Guyer D Br J Ophthalmol; 2008 Dec; 92(12):1606-11. PubMed ID: 18614570 [TBL] [Abstract][Full Text] [Related]
6. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review. Kourlas H; Schiller DS Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578 [TBL] [Abstract][Full Text] [Related]
7. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]. Maier M; Feucht N; Huebner M; Lohmann C Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780 [TBL] [Abstract][Full Text] [Related]
8. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Quiram PA; Hassan TS; Williams GA Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008 [TBL] [Abstract][Full Text] [Related]
9. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series. Atmani K; Coscas F; Coscas G; Soubrane G Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083 [TBL] [Abstract][Full Text] [Related]
10. Pegaptanib for neovascular age-related macular degeneration. Maberley D Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440 [TBL] [Abstract][Full Text] [Related]
12. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review. Takeda AL; Colquitt J; Clegg AJ; Jones J Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication]. Larsen M; Sander B; Villumsen JE; Haamann PH; la Cour M; Lund-Andersen H; Ugeskr Laeger; 2005 Aug; 167(35):3301-5. PubMed ID: 16138974 [TBL] [Abstract][Full Text] [Related]
14. [Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial]. Pegaptanib Sodium Multi-center Study Group Nippon Ganka Gakkai Zasshi; 2011 Feb; 115(2):122-33. PubMed ID: 21400918 [TBL] [Abstract][Full Text] [Related]
15. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation. Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575 [TBL] [Abstract][Full Text] [Related]